- Although price ZSCore is at a high level but it has returned from prior high level and momentum has slowed down.
- RSI is at a high level of 84. A high level of RSI indicates the stock is overbought.
- MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Investors need to pay close attention to Synlogic (SYBX) stock based on the movements in the options market lately.
A look at the shareholders of Synlogic, Inc. ( NASDAQ:SYBX ) can tell us which group is most powerful. Large companies...
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined significant clinical milestones for 2021 and provided an overview of recent progress.
Synlogic shares skyrocketed Monday after the biopharmaceutical company announced progress on its SYNB1891 drug for solid tumors and lymphoma. Synlogic recently traded at $2.97, up 32.59%. The drug was being advanced "due to acceptable safety at doses evaluated to date, intra-tumoral injection feasibility, successful escalation to clinically relevant dose levels, and evidence of target engagement and immune system up-regulation," Synlogic said.
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial. SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient's immune response.
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Michael Heffernan to its board of directors.
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present additional translational and in silico data on SYNB8802, a Synthetic Biotic medicine for the treatment of Enteric Hyperoxaluria, during the American Institute of Chemical Engineers (AIChE) 3rd International Conference on Microbiome Engineering (ICME) on December 7-9, 2020.
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]